Asieris(SH:688176)2024-04-29 10:31Financial Performance - The company's operating revenue for Q1 2024 was ¥24,319,537.45, representing a significant increase compared to the previous year[4] - The net profit attributable to shareholders was a loss of ¥82,848,207.86, reflecting ongoing challenges in profitability[4] - Total operating revenue for Q1 2024 was CNY 24,319,537.45, an increase from CNY 22,874.40 in Q1 2023, representing a growth of approximately 6,339.5%[18] - Net profit for Q1 2024 was a loss of CNY 82,969,385.29, compared to a loss of CNY 62,934,818.03 in Q1 2023, reflecting a deterioration of approximately 31.9%[19] - The basic earnings per share for the period was -¥0.15, primarily due to increased net losses[7] - The company reported a basic earnings per share of -CNY 0.15 for Q1 2024, compared to -CNY 0.11 in Q1 2023[19] Research and Development - Research and development expenses totaled ¥68,099,878.30, which is an increase of 19.74% year-over-year[4] - The company continues to invest heavily in R&D, with a focus on developing core products that are still in the research phase[7] - Research and development expenses for Q1 2024 amounted to CNY 68,099,878.30, compared to CNY 56,872,414.28 in Q1 2023, marking an increase of about 19.8%[18] Cash Flow and Liquidity - The company reported a net cash flow from operating activities of -¥129,110,035.08, indicating increased cash outflows[4] - Cash flow from operating activities for Q1 2024 was a net outflow of CNY 129,110,035.08, worsening from a net outflow of CNY 76,863,840.88 in Q1 2023[21] - The company’s total cash inflow from operating activities was CNY 26,465,560.01 in Q1 2024, significantly higher than CNY 3,626,159.51 in Q1 2023[21] - As of March 31, 2024, the company's cash and cash equivalents amounted to RMB 2,105,888,987.91, an increase of 21.1% from RMB 1,738,214,569.80 on December 31, 2023[13] - The total cash and cash equivalents at the end of Q1 2024 amounted to $775.17 million, down from $1.51 billion at the end of Q1 2023[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,558,052,535.71, down 2.82% from the end of the previous year[5] - The total current assets decreased to RMB 2,305,728,450.84 from RMB 2,375,453,052.65, reflecting a decline of approximately 2.9%[14] - The company's short-term borrowings increased to RMB 109,900,000.00 from RMB 73,400,000.00, representing an increase of 49.6%[15] - The total liabilities rose to RMB 257,810,807.05 from RMB 242,501,735.11, indicating an increase of about 6.3%[15] - The total assets decreased to RMB 2,558,052,535.71 from RMB 2,632,270,467.20, a decline of approximately 2.8%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 29,929[9] - The equity attributable to shareholders decreased by 3.74% to ¥2,298,581,382.99 compared to the previous year[5] Investment and Other Income - The company recorded investment income of CNY 7,951,174.26 in Q1 2024, up from CNY 2,796,161.24 in Q1 2023, representing an increase of about 184.5%[18] - Other comprehensive income after tax for Q1 2024 was a loss of CNY 1,115,257.61, compared to a gain of CNY 103,230.26 in Q1 2023[19] Development Decisions - The company decided to terminate the further development of APL-1202 in combination with chemotherapy for the treatment of high-risk non-muscle invasive bladder cancer due to not meeting primary study endpoints[11] Accounting and Reporting - The report was presented by PAN KE, with accounting responsibilities held by Yang Mingyuan and Hu Haiyao[22] - The company is not applying new accounting standards or interpretations for the first time in 2024[22]